BiotechTube

GW810781

Phase 2Completed
1 views this week 0 watching💤 Quiet
Interest: 35/100
35
Hype Score

Development Stage

✓
Pre-clinical
✓
Phase 1
3
Phase 2
4
Phase 3
5
Approved
Indication / Disease

HIV Infections

Conditions

HIV Infections

Trial Timeline

Jun 1, 2002 → Jan 1, 2003

NCT ID
NCT00046332

About GW810781

GW810781 is a phase 2 stage product being developed by Shionogi for HIV Infections. The current trial status is completed. This product is registered under clinical trial identifier NCT00046332. Target conditions include HIV Infections.

What happened to similar drugs?

20 of 20 similar drugs in HIV Infections were approved

Approved (20) Terminated (3) Active (0)
✅amphotericin B liposomal (Ambisome)Astellas PharmaApproved
✅Ciclosporin and Mycophenolate-mofetil + Tacrolimus and Mycophenolate-mofetil + Tacrolimus and Mycophenolate-mofetil with change from Mycophenolate-mofetil to EverolimusAstellas PharmaApproved
✅Ceftaroline fosamil + Ceftriaxone plus vancomycinAstraZenecaApproved
✅Kaletra + Isentress + Pre-study antiretroviral regimenMerckApproved
✅HPV9vMerckApproved
✅Vancomycin + Daptomycin + Semi-Synthetic PenicillinMerckApproved
✅Daptomycin + VancomycinMerckApproved

Hype Score Breakdown

Clinical
12
Activity
8
Company
15
Novelty
0
Community
0

Clinical Trials (1)

NCT IDPhaseStatus
NCT00046332Phase 2Completed

Competing Products

20 competing products in HIV Infections

See all competitors
ProductCompanyStageHype Score
DFA-02 Antibiotic Gel + DFA-02 Placebo GelDr. Reddy's LaboratoriesPhase 2
32
AAVLP-HPV + Placebo2A PharmaPhase 1
19
VN-0200 + PlaceboDaiichi SankyoPhase 1
29
VN-0200Daiichi SankyoPhase 2
35
MicafunginAstellas PharmaPre-clinical
26
amphotericin B liposomal (Ambisome)Astellas PharmaApproved
43
Parenteral micafungin application + Other parenteral antifungal drugsAstellas PharmaPre-clinical
26
Ciclosporin and Mycophenolate-mofetil + Tacrolimus and Mycophenolate-mofetil + Tacrolimus and Mycophenolate-mofetil with change from Mycophenolate-mofetil to EverolimusAstellas PharmaApproved
43
MicafunginAstellas PharmaPre-clinical
26
MicafunginAstellas PharmaPhase 1
29
Micafungin + PlaceboAstellas PharmaPhase 3
32
Cefiderocol + Standard of CareShionogiPhase 2
35
Dolutegravir + Rlipivirine + GSK1265744ShionogiPhase 1
29
Xeruborbactam Oral Prodrug + CeftibutenShionogiPhase 1
29
Cefiderocol + Standard of CareShionogiPhase 2
35
Dolutegravir 50 mg twice daily + Dolutegravir placebo twice dailyShionogiPhase 3
40
Xeruborbactam Oral Prodrug + Ceftibuten + Xeruborbactam Oral Prodrug Placebo + Ceftibuten PlaceboShionogiPhase 1
29
Dolutegravir 50 mg tablet + Dolutegravir 50 mg oral granulesShionogiPhase 1
29
GSK1349572 + Placebo + Iohexol Injection + Para-aminohippurate infusionShionogiPhase 1
29
CefiderocolShionogiPhase 2
35